Key facts: 4D Molecular Therapeutics reports positive trial results; Scott Bizily files Form 144
I'm PortAI, I can summarize articles.
4D Molecular Therapeutics (FDMT) announced positive interim Phase 1 trial results for 4D-710, showing lasting lung function improvements in cystic fibrosis patients and a good safety profile.1On December 16, 2025, Scott Bizily of 4D Molecular Therapeutics (FDMT) filed a Form 144 to sell 1,635 restricted shares under a prearranged trading plan.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments